CPI-613

CPI-613 is a non-redox active lipoate derivative that acts as a selective inhibitor mitochondrial enzymes pyruvate dehydrogenase (PDH) and alpha-ketoglutarate dehydrogenase. In vitro; CPI-613 dose-dependently and efficiently kills H460 human lung cancer cells and Saos-2 human sarcoma cells. In vitro; CPI-613 treatment potently disrupts H460 cancer cell mitochondrial metabolism including inhibition of PDH complex activity. CPI-613 treatment also leads to loss of mitochondrial membrane potential as assessed by JC-1 mitochondrial uptake. CPI-613 also induces apoptotic and non-apoptotic cell death in the cells of H460 human lung cancer and Saos-2 human sarcoma in vitro. 

Small volumes of CPI-613 biochemical vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS845664 is a biochemical targeting CPI-613.